• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Comera Life Sciences Announces Process Exploring Strategic Alternatives

    12/6/23 8:30:00 AM ET
    $CMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMRA alert in real time by email

    WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value.

    As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms. If the Company is unable to complete a transaction, it may be required to seek a reorganization, liquidation or other restructuring. The Company does not expect to disclose or provide an update concerning developments related to this process unless or until the Company's Board of Directors has approved a definitive course of action or otherwise determines that other disclosure is necessary or appropriate jurisdiction.

    About Comera Life Sciences

    Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.

    To learn more about the Comera Life Sciences' mission, as well as the proprietary SQore™ platform, visit https://comeralifesciences.com/.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events including statements related to the Company's review and evaluation of potential strategic alternatives and their impact on stockholder value; the process by which the Company engages in evaluation of strategic alternatives; the Company's ability to identify potential merger or acquisition partners; the Company's ability to raise capital to continue as a going concern; and the terms, timing, structure, benefits and costs of any strategic transaction and whether one will be consummated at all; and the impact of any strategic transaction on the Company. These forward-looking statements are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: the results of our strategic review process; our ability to raise capital; cash flow, cash burn, expenses, obligations and liabilities; the interest of third parties in entering into a merger, reverse merger, or other strategic transaction with the Company; the outcomes of any litigation, regulatory proceedings, inquiries or investigations that we may become subject to; and other important factors discussed in the Company's filings with the Securities and Exchange Commission. If we do not obtain additional equity or debt funding, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our business relationships with third parties. If we do not have sufficient funds to continue operations or satisfy our liabilities, we could be required to seek a reorganization, liquidation or other restructuring that could result in our stockholders losing some or all of their investment in us. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Comera assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Comera can give no assurance that it will achieve its expectations.

    Contacts

    Comera Investor

    John Woolford

    ICR Westwicke

    [email protected]

    Comera Press

    Jon Yu

    ICR Westwicke

    [email protected]



    Primary Logo

    Get the next $CMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option

      WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to

      1/4/24 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Announces Process Exploring Strategic Alternatives

      WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a

      12/6/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Campbell Michael Gerard bought $708 worth of shares (10,000 units at $0.07), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      11/28/23 4:25:36 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    SEC Filings

    See more

    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:18 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:27 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:16 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Comera Life Sciences Holdings Inc.

      SC 13D - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      1/5/24 7:16:15 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13D/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/7/23 8:05:22 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13G/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/6/23 4:24:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Konar Shameek

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:48:13 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Konar Shameek claimed ownership of 1,001,064 shares (SEC Form 3)

      3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:47:03 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Denny George P Iii

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      1/11/24 7:14:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORS

      Appointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member. "HDAX's platform technology has great potential to deliver breakthrough treatments where there is high unmet need.""We are please

      4/11/23 9:04:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Janice Marie McCourt as Chief Business Officer

      WOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced the appointment of Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities, and driving the execution of the Company's commercial strategy. Ms. McCourt will report to Jeffrey Hackman, Chairman and CEO, and serve on the Company's executive leadership te

      11/9/22 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Financials

    Live finance-specific insights

    See more
    • Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

      – Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – –   Completed previously announced $4.1 million private placement of shares of Comera's common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety,

      11/9/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

      – Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued listing of its common stock, subject to Comera's satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN

      8/10/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights

      – Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera's patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 (GLOBE NEWSWIRE) --  Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ende

      5/11/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care